Advertisement

Search Results

Advertisement



Your search for Christopher Sweeney, MBBS matches 21 pages

Showing 1 - 21


prostate cancer

ENZAMET Trial Shows Enzalutamide Improves Overall Survival in Hormone-Sensitive Metastatic Prostate Cancer

Agents that improve survival in metastatic castration-resistant prostate cancer when added to background androgen-deprivation therapy (ADT) are showing success in treating metastatic prostate cancer earlier while it is still hormone-sensitive. These agents include docetaxel (chemotherapy) and...

bladder cancer
kidney cancer
prostate cancer
solid tumors

Christopher Sweeney, MBBS, and Ian D. Davis, MBBS, PhD, on ANZUP: Taking a Multidisciplinary Approach to Prostate, Kidney, Bladder, Testicular, and Penile Cancers

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Ian D. Davis, MBBS, PhD, of Monash University and Eastern Health, discuss the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, working globally to speed clinical research in and treatment of urogenital cancers.

prostate cancer

2019 ASCO: ENZAMET: Addition of Enzalutamide to Standard of Care in Metastatic Hormone-Sensitive Prostate Cancer

An interim analysis of the international, randomized phase III ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer who received the nonsteroidal antiandrogen agent enzalutamide along with standard-of-care treatment were alive after 3 years, compared with 72% of men ...

prostate cancer

Ian D. Davis, MBBS, PhD, and Christopher Sweeney, MBBS, on Prostate Cancer: ENZAMET Trial on Enzalutamide for Metastatic Hormone-Sensitive Disease

Ian D. Davis, MBBS, PhD, of Monash University and Eastern Health, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss phase III findings from their international trial on adding enzalutamide as a new treatment option with testosterone suppression for metastatic hormone-sensitive ...

prostate cancer

Prostate Cancer Foundation and Movember Foundation Announce 2018 Winners of Challenge Awards

The Prostate Cancer Foundation (PCF) and the Movember Foundation recently announced four new Movember Foundation–PCF Challenge Award teams at some of the world’s leading academic research institutions will receive a total of $3.5 million to support cross-disciplinary pioneering research toward the...

prostate cancer

Long-Term Survival Outcomes With Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Analysis of long-term survival outcomes in the phase III CHAARTED trial showed a survival advantage with the addition of docetaxel to androgen-deprivation therapy (ADT) in patients with hormone-sensitive metastatic prostate cancer, although no advantage was observed among patients with low-volume...

prostate cancer

PSA at 7 Months and Prognosis in Metastatic Hormone-Sensitive Prostate Cancer Treated With ADT With or Without Chemotherapy

In a study reported in the Journal of Clinical Oncology, Harshman et al found that a prostate-specific antigen (PSA) level ≤ 0.2 ng/mL at 7 months after the start of androgen-deprivation therapy (ADT) was significantly associated with longer overall survival in metastatic...

prostate cancer

Metastasis-Free Survival as Surrogate for Overall Survival in Localized Prostate Cancer

In a meta-analysis reported in the Journal of Clinical Oncology, Xie et al found that metastasis-free survival was a strong surrogate for overall survival in patients with localized prostate cancer, potentially providing a metric that could accelerate assessment of new adjuvant therapy approaches. ...

prostate cancer

Deep Androgen Suppression Plus Abiraterone and Prednisone: Effective Strategy for Hormone-Naive Prostate Cancer

ANTAGONISM OF THE ANDROGEN AXIS remains a cornerstone of systemic therapy for high-risk localized and metastatic prostate cancer, reflecting the central role of androgen-dependent biologic mechanisms in hormone-naive disease. Despite the use of standard androgen-deprivation therapy, men with...

prostate cancer

Christopher J. Sweeney, MBBS, on Prostate Cancer: CHAARTED Trial Follow-up

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)

prostate cancer

Christopher J. Sweeney, MBBS, on Localized Prostate Cancer: Metastasis-Free Survival as a Surrogate for Overall Survival

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermediate and high-risk prostate cancer. (Abstract 717O)

solid tumors
issues in oncology

Insurance Status Impacts Survival, According to Two New Studies

Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study found. The findings, published by Markt et al in Cancer, add to growing evidence that differences in health insurance status can affect...

prostate cancer

Howard M. Sandler, MD, and Christopher Sweeney, MBBS, on Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discuss the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).

prostate cancer

Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute discusses the EnzaMet and EnzaRad study designs, eligibility requirements, and endpoints (Abstracts TPS5077 and TPS5078).

solid tumors

Christopher J. Sweeney, MBBS: Testicular Cancer Update

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, reviews important presentations on testicular cancer, including dose intensification for first-line therapy of metastatic disease, and what physicians need to know about the molecular genetics of testicular cancer.

My First of Many ASCO Meetings

In June, I attended my first ASCO Annual Meeting. Although I have been practicing and teaching urology for 35 years with a specific interest in genitourinary oncology and I have attended dozens of national meetings, the ASCO Annual Meetings were not on my radar. Focus on the Patient The...

prostate cancer

‘Unprecedented’ Survival Benefit in Prostate Cancer With Addition of Docetaxel to Hormone Therapy

Adding docetaxel to standard androgen ablation therapy (ie, testosterone suppression) extended survival by more than 1 year in men with newly diagnosed metastatic hormone-sensitive prostate cancer in the phase III E3805 trial, funded by the National Institutes of Health. As reported at the ASCO...

Expert Point of View: Christopher J. Sweeney, MBBS

These latest results of STAMPEDE lend further support to the early use of chemotherapy in men with advanced prostate cancer. They confirm the CHAARTED trial results reported last year by Christopher J. Sweeney, MBBS, which were practice-changing. Men with newly diagnosed metastatic...

CHAARTED and GETUG-15 Studies

At the 2014 ASCO Annual Meeting, the phase III E3805 (CHAARTED) trial presented at the Plenary Session showed that the addition of docetaxel to standard hormone therapy extended survival by more than 1 year in men with newly diagnosed, hormone-sensitive prostate cancer.1 The survival benefit of...

prostate cancer

Adding Docetaxel to Androgen-Deprivation Therapy Prolongs Overall Survival in Metastatic Prostate Cancer

In a phase III trial (E3805) reported in The New England Journal of Medicine, Christopher J. Sweeney, MBBS, of Dana-Farber Cancer Institute, Boston, and colleagues found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median...

prostate cancer

ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer

The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...

Advertisement

Advertisement



Advertisement